Close Menu

NEW YORK – Blood-based cancer detection firm Thrive Earlier Detection said Wednesday that it has raised $257 million in a Series B financing round led by Casdin Capital and Section 32.

Also participating were investors from the Series A round, including Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital, Sands Capital, funds and accounts advised by T. Rowe Price Associates, and other unnamed investors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.